A Low Dose of Pasireotide Prevents Hypoglycemia in Roux-en-Y Gastric Bypass-Operated Individuals

Caroline C. Ohrstrom; Dorte L. Hansen; Urd Lynge Kielgast; Bolette Hartmann; Jens Juul Holst; Dorte Worm

doi:10.1007/s11695-019-04248-x

A Low Dose of Pasireotide Prevents Hypoglycemia in Roux-en-Y Gastric Bypass-Operated Individuals

Caroline C. Ohrstrom, Dorte L. Hansen, Urd Lynge Kielgast, Bolette Hartmann, Jens Juul Holst, Dorte Worm

3 Citationer (Scopus)

Abstract

Post-bariatric hypoglycemia (PBH) can be a serious complication after Roux-en-Y gastric bypass (RYGB), and treatment with somatostatin analogs has been suggested. We investigated the acute effects of three different doses of pasireotide (75 μg, 150 μg, and 300 μg) on the postprandial glucose metabolism in five RYGB-operated individuals with PBH using a mixed meal test. All three doses prevented hypoglycemia but were associated with a notable increase in postprandial hyperglycemia. Moreover, all doses greatly diminished insulin, C-peptide, and glucagon-like peptide-1 responses. Considering its strong hyperglycemic potential, we suggest that pasireotide should be administered carefully in RYGB-operated individuals with PBH, and if necessary, a 75 μg dose seems sufficient to prevent hypoglycemia.

Originalsprog	Engelsk
Tidsskrift	Obesity Surgery
Antal sider	6
ISSN	0960-8923
DOI	https://doi.org/10.1007/s11695-019-04248-x
Status	Udgivet - 1 apr. 2020

Adgang til dokumentet

10.1007/s11695-019-04248-x

Citationsformater

@article{5a0db06450904d6896709e2e4ac3d1c8,

title = "A Low Dose of Pasireotide Prevents Hypoglycemia in Roux-en-Y Gastric Bypass-Operated Individuals",

abstract = "Post-bariatric hypoglycemia (PBH) can be a serious complication after Roux-en-Y gastric bypass (RYGB), and treatment with somatostatin analogs has been suggested. We investigated the acute effects of three different doses of pasireotide (75 μg, 150 μg, and 300 μg) on the postprandial glucose metabolism in five RYGB-operated individuals with PBH using a mixed meal test. All three doses prevented hypoglycemia but were associated with a notable increase in postprandial hyperglycemia. Moreover, all doses greatly diminished insulin, C-peptide, and glucagon-like peptide-1 responses. Considering its strong hyperglycemic potential, we suggest that pasireotide should be administered carefully in RYGB-operated individuals with PBH, and if necessary, a 75 μg dose seems sufficient to prevent hypoglycemia.",

keywords = "Gastric bypass, Hypoglycemia, Hyperglycemia, Pasireotide, Somatostatin analogs",

author = "Ohrstrom, {Caroline C.} and Hansen, {Dorte L.} and Kielgast, {Urd Lynge} and Bolette Hartmann and Holst, {Jens Juul} and Dorte Worm",

year = "2020",

month = apr,

day = "1",

doi = "10.1007/s11695-019-04248-x",

language = "English",

journal = "Obesity Surgery",

issn = "0960-8923",

publisher = "Springer",

}

TY - JOUR

T1 - A Low Dose of Pasireotide Prevents Hypoglycemia in Roux-en-Y Gastric Bypass-Operated Individuals

AU - Ohrstrom, Caroline C.

AU - Hansen, Dorte L.

AU - Kielgast, Urd Lynge

AU - Hartmann, Bolette

AU - Holst, Jens Juul

AU - Worm, Dorte

PY - 2020/4/1

Y1 - 2020/4/1

N2 - Post-bariatric hypoglycemia (PBH) can be a serious complication after Roux-en-Y gastric bypass (RYGB), and treatment with somatostatin analogs has been suggested. We investigated the acute effects of three different doses of pasireotide (75 μg, 150 μg, and 300 μg) on the postprandial glucose metabolism in five RYGB-operated individuals with PBH using a mixed meal test. All three doses prevented hypoglycemia but were associated with a notable increase in postprandial hyperglycemia. Moreover, all doses greatly diminished insulin, C-peptide, and glucagon-like peptide-1 responses. Considering its strong hyperglycemic potential, we suggest that pasireotide should be administered carefully in RYGB-operated individuals with PBH, and if necessary, a 75 μg dose seems sufficient to prevent hypoglycemia.

AB - Post-bariatric hypoglycemia (PBH) can be a serious complication after Roux-en-Y gastric bypass (RYGB), and treatment with somatostatin analogs has been suggested. We investigated the acute effects of three different doses of pasireotide (75 μg, 150 μg, and 300 μg) on the postprandial glucose metabolism in five RYGB-operated individuals with PBH using a mixed meal test. All three doses prevented hypoglycemia but were associated with a notable increase in postprandial hyperglycemia. Moreover, all doses greatly diminished insulin, C-peptide, and glucagon-like peptide-1 responses. Considering its strong hyperglycemic potential, we suggest that pasireotide should be administered carefully in RYGB-operated individuals with PBH, and if necessary, a 75 μg dose seems sufficient to prevent hypoglycemia.

KW - Gastric bypass

KW - Hypoglycemia

KW - Hyperglycemia

KW - Pasireotide

KW - Somatostatin analogs

U2 - 10.1007/s11695-019-04248-x

DO - 10.1007/s11695-019-04248-x

M3 - Journal article

C2 - 31709494

SN - 0960-8923

JO - Obesity Surgery

JF - Obesity Surgery

ER -

A Low Dose of Pasireotide Prevents Hypoglycemia in Roux-en-Y Gastric Bypass-Operated Individuals

Abstract

Adgang til dokumentet

Fingeraftryk

Citationsformater